

Integrated Use of IVUS and FFR for LM Stenting

Gary S. Mintz, MD

Cardiovascular Research Foundation





Four studies have highlighted the inaccuracy of angiography in the assessment of LMCA disease

- Fisher et al. Cathet Cardiovasc Diagn 1982;8:565-75
- Cameron et al. Circulation 1983;68:484-489
- Lindstaedt et al. Int J Cardiol 2007;120:254-61
 - In 51 patients unanimous correct assessment of LM severity by 4 experienced interventional cardiologists was only 29%
- Hamilos et al. Circulation 2009;120:1505-12
 - In 209 patients two reviewers either disagreed whether the LM was significant or they agreed and were wrong in their assessment of LM severity in 49%

IVUS vs FFR in LMCA Disease

- There is more agreement between IVUS and FFR in assessing LMCA than in assessing non-LMCA lesions
 - Limited variability in (short) LMCA length
 - Limited variability in large LMCA size
 - Limited variability in amount of supplied myocardium
- Both have theoretical and practical limitations
 - FFR
 - Proximal LAD and/or LCX disease may affect FFR of LMCA
 - IVUS
 - Especially in distal LMCA lesions, it is necessary to image from both the LAD and LCX
 - It is not possible to assess the LCX from an LAD-to-LM pullback, and it is not possible to assess the LAD from an LCX-to-LM pullback

IVUS Determinants of LMCA FFR <0.75




IVUS determinants of LM FFR (n=47)

Independent predictors for FFR (continuous variable)


- *MLA* ($\beta=0.58$, 95% CI=0.02-0.04, $p<0.001$)
- *Plaque rupture* ($\beta=-0.24$, 95% CI= -0.09-0.01, $p=0.036$)

MLA predicting FFR<0.80




Sensitivity 83%
Specificity 83%
PPV 83%
NPV 83%
Accuracy 83%

PB predicting FFR<0.80



Sensitivity 78%
Specificity 75%
PPV 75%
NPV 78%
Accuracy 77%



	Men	Women
South Korea	68.6 kg	56.5 kg
US	88.3 kg	74.7 kg

Heart weight correlates directly with body weight (r=0.8-0.9)


Kang et al. JACC Cardiovasc Interv 2011;4:1168-74

Yoon et al. Korean J Path 1999;33:1-8

Seo et al. J Korean Med Sci 2000;15:641-6

LMCA disease is rarely isolated (6-9%)

- *An in vitro model suggests that positioning the FFR guidewire in the LCX will not accurately reflect the LMCA only if the composite FFR in the LMCA+LAD is ≤ 0.65 .*
- *An in vivo ovine model suggests that an FFR in the uninvolved artery will not accurately reflect the LMCA only if the composite FFR in the LMCA+the involved artery is ≤ 0.50 and that an FFR > 0.85 would indicate that the LMCA is not functionally significant.*



Ragosta et al. *Catheter Cardiovasc Interv* 2006;67:357-72



Capodanno et al. *JACC Cardiovasc Interv* 2009;2:731-8

Daniels et al. *JACC Cardiovasc Interv* 2012;5:1021-5


Young et al. *Circ Cardiovasc Interv* 2013, in press




- *In 25% of patients, MLA differs by 1mm² when imaged from a pullback beginning in the LAD vs the LCX.*
- *Since IVUS can artificially increase, but not decrease lumen dimensions, the smallest MLA is always the most accurate*



Evaluation of the LAD from the LM-LCX pullback







Evaluation of the LCX from the LM-LAD pullback











	Sensitivity	Specificity
Plaque burden >40%	59%	45%
Plaque burden >70%	78%	42%




	Sensitivity	Specificity
Plaque burden >40%	67%	55%
Plaque burden >70%	88%	42%





IVUS plaque distribution in 140 distal LMCA bifurcation lesions








Outcomes in 136 pts with an FFR >0.8 managed medically vs 73 pts with an FFR <0.8 managed surgically





- A RCA stenosis was the sole independent predictor for MACE.
- MACE survival rates at 5 years in the medical and surgical groups were 70% and 66%, respectively, P=0.54.


Prospective application of predefined IVUS criteria for revascularization of intermediate LM lesions: Results at 2 years from the LITRO study



Clinical outcome of pts with vs without revascularization





Clinical outcome of pts without revascularization according to the MLA



In the group of 16 patients with MLA $< 6\text{mm}^2$ who were treated medically, cardiac death-free survival to 2 years was 86% (97.7% in the deferred group; $p=0.04$), and survival free of cardiac death, MI, and revascularization was 62.5% (87.3% in the deferred group; $p=0.02$).

“Small” LM = Diffuse LMCA disease



- Murray's Law

- $LMCA^3 = LAD^3 + LCX^3$


- Fractal Geometry

- $LMCA^D = 0.678 (LAD^D + LCX^D)$

QCA				
E = 0.678 * (C+D)				
LMDref (A)	(mm)	4.80	2.69	4.09
LMMLD (B)	(mm)	4.70	2.62	2.58
Diameter Stenosis	(%)	2	3	37
LADDref (C)	(mm)	3.93	3.32	3.72
LCxDref (D)	(mm)	3.17	2.28	3.13
LMDfractal (E)	(mm)	4.81	3.80	4.64
Diameter Stenosis fractal	(%)	2	31	44
LMDref-LMDfractal	(mm)	-0,01	-1,11	-0,55

QIVUS				
LM MLA (F)	(mm ²)	15.32	6.02	4.42
LMMI PB (G)	(%)	17	66	65
LMMLEEM (H)	(mm ²)	18.45	17.58	12.76
LMDref	(mm)	4.44	2.88	4.09
LMMLD	(mm)	4.42	2.77	2.37
Diameter Stenosis	(%)	1	4	42
LADDref	(mm)	3.95	3.70	3.73
LCxDref	(mm)	3.04	2.60	2.94
LMDfractal	(mm)	4.74	4.27	4.52
Diameter Stenosis fractal	(%)	7	35	48
LMDref-LMDfractal	(mm)	-0.30	-1.39	-0.43


Criteria for stent underexpansion at the distal LMCA bifurcation (n=403)



- **MACE-free survival was lower in pts with underexpansion vs those without underexpansion (89.4% vs 98.1%)**
- **TLR-free survival was lower in pts with underexpansion vs no underexpansion (90.9% vs 98.5%).**
- **Although acute malapposition was observed in 28 pts, malapposition was not related to MACE at follow-up.**

Impact of underexpansion on ISR in patients treated with either two stents or a single stent cross-over


Two-Stent Techniques (n=114) One-stent Cross-over (n=289)



MAIN-COMPARE Registry

- 975 pts with unprotected LMCA stenosis underwent elective stenting under IVUS (n=756) or angiographic (n=219) guidance and were followed for 3 years
- IVUS-guidance was significantly associated with reduced death (HR=0.31 overall and HR=0.27 in DES) as compared with angiography guidance
- However, the use of IVUS-guidance did not reduce the risk of myocardial infarction or target vessel revascularization.

All-Cause Mortality After LMCA DES Implantation: Impact of IVUS Guidance



ADAPT-DES – IVUS vs No-IVUS Cohort -

Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents

8,575 pts prospectively enrolled
No clinical or anatomic exclusion
criteria

11 sites in US and Germany

PCI with ≥ 1 non-investigational DES
Successful and uncomplicated

IVUS Use: 3349 pts

No IVUS: 5234 pts



Clinical FU at 30 days, 1 year

Impact of Complexity of Procedure on MACE

— IVUS Use
— No IVUS Use

One vessel treatment





≥2 vessel or left main or bifurcation treated





at risk:

	0	3	6	9	12
IVUS +	2538	2429	2399	2376	2256
IVUS -	3669	3466	3429	3387	3113



	0	3	6	9	12
IVUS +	802	768	760	753	702
IVUS -	1520	1424	1409	1399	1305



FFR of “Jailed” LCX




43 LMCA bifurcation lesions with a pre-PCI LCX ostial DS<50% were treated by single-stent cross-over



MLA <3.7mm²

- Sensitivity 100%
- Specificity 71%
- PPV 16%
- NPV 100%




Plaque Burden >56%

- Sensitivity 100%
- Specificity 65%
- PPV 14%
- NPV 100%


MLA within LCX ostium

5.4mm² → 4.0mm²




EEM area at MLA

11.8mm² → 9.6mm²







EEM eccentricity

1.22 → 1.47



78% showed a >10% reduction of MLA within LCX ostium after cross-over stenting

Carina shift



Conclusions

- **Use IVUS or FFR to assess LMCA severity**
 - **FFR <0.80**
 - **MLA <6mm² in Western patients**
 - **MLA <4.8mm² in Asian patients**
- **Perform pre-intervention IVUS from both the LAD and LCX to assess the extent of the atherosclerosis**
- **Perform post-intervention IVUS to optimize the implanted stent results**